Download Highlights from the San Antonio Breast Cancer Symposium 2015

Downloaded from http://esmoopen.bmj.com/ on May 3, 2017 - Published by group.bmj.com
Open Access
Podcast
Highlights from the San Antonio Breast
Cancer Symposium 2015
Jacek Jassem
To cite: Jassem J. Highlights
from the San Antonio Breast
Cancer Symposium 2015.
ESMO Open 2016;1:e000043.
doi:10.1136/esmoopen-2016000043
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
esmoopen-2016-000043).
Accepted 5 February 2016
Department of Oncology and
Radiotherapy, Medical
University of Gdansk,
Gdansk, Poland
Correspondence to
Professor Jacek Jassem;
[email protected]
https://soundcloud.com/bmjpodcasts/highlights-from-san-antonio-breast-cancersymposium-2015
A critical review on the practice changing
studies presented at the San Antonio Breast
Cancer Symposium, held December 2015, is
presented in this podcast. A number of
areas, including neoadjuvant and adjuvant
treatment, treatment of metastatic disease
and the emergence of new biomarkers are
addressed. Trials discussed include the
WSG-ADAPT HER2+/HR+ phase II trial,
which assessed 12-weeks of neoadjuvant
TDM1 with or without endocrine therapy
versus trastuzumab+endocrine therapy in
HER2-positive
hormone-receptor-positive
early breast cancer, the CREATE-X study,
which assessed adjuvant capecitabine in
patients with HER2-negative pathologic
residual invasive disease after neoadjuvant
chemotherapy, and the TH3RESA study,
which investigated trastuzumab emtansine
use in patients with previously treated
HER2-positive metastatic breast cancer.
Further, studies on new promising biomarkers such as the prognostic value of circulating tumour cells in follow up of early breast
cancer patients after adjuvant chemotherapy
are highlighted. Overall, the present podcast
represents a comprehensive overview on
some of the most important studies presented at the San Antonio Breast Cancer
Symposium.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer
reviewed.
Open Access This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 4.0) license, which permits others to
distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different
terms, provided the original work is properly cited and the use
is non-commercial. See: http://creativecommons.org/licenses/
by-nc/4.0/
Jassem J. ESMO Open 2016;1:e000043. doi:10.1136/esmoopen-2016-000043
1
Downloaded from http://esmoopen.bmj.com/ on May 3, 2017 - Published by group.bmj.com
Highlights from the San Antonio Breast
Cancer Symposium 2015
Jacek Jassem
ESMO Open 2016 1:
doi: 10.1136/esmoopen-2016-000043
Updated information and services can be found at:
http://esmoopen.bmj.com/content/1/1/e000043
These include:
Open Access
This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms,
provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Email alerting
service
Receive free email alerts when new articles cite this article. Sign up in the
box at the top right corner of the online article.
Topic
Collections
Articles on similar topics can be found in the following collections
Open access (102)
Notes
To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions
To order reprints go to:
http://journals.bmj.com/cgi/reprintform
To subscribe to BMJ go to:
http://group.bmj.com/subscribe/